Sinopharma drops Phase 3 vaccine trial in Philippines
Dr. Jaime Montoya, executive director of the Department of Science and Technology-Philippine Council for Health Research and Development, said the decision of the foreign pharmaceutical came after the DOST-PCHRD declined a proposal of Sinopharma for a co-financing scheme.
AFP/Noel Celis
Sinopharma drops Phase 3 vaccine trial in Philippines
Rainier Allan Ronda (The Philippine Star) - October 22, 2020 - 12:00am

MANILA, Philippines — Chinese pharmaceutical firm Sinopharma will not pursue an earlier plan to conduct Phase 3 clinical trials of the candidate COVID-19 vaccine it is developing in the Philippines.

Dr. Jaime Montoya, executive director of the Department of Science and Technology-Philippine Council for Health Research and Development, said the decision of the foreign pharmaceutical came after the DOST-PCHRD declined a proposal of Sinopharma for a co-financing scheme.

“I think it is not really that they backed out,” Montoya told The STAR. “They just decided not to do Phase 3 clinical trials in the Philippines. They wanted a co-funding arrangement but the government is only committed to support the WHO Solidarity Trials. We have limited funds.”

Montoya, however, said that Sinopharma will still sell a COVID-19 vaccine that they will develop.

“But I think they are still interested in marketing the vaccine in the Philippines,” Montoya said.

The DOST-PCHRD is providing the P89.1-million funding for the conduct of Phase 3 clinical trials of candidate COVID-19 vaccines being developed by foreign pharmaceuticals and institutions.

Sinopharma is one of six foreign institutions and pharmaceutical companies that signed a Confidentiality Data Agreement (CDA) with the PCHRD – a requirement for most of them before handing over data on Phase 1 and 2 clinical trials that is needed for the Philippines’ DOST and Food and Drug Administration to review, prior to approving the conduct of Phase 3 vaccine clinical trials.

Montoya said there are some foreign pharmaceuticals developing candidate COVID-19 vaccines that did not require a CDA prior to handing over data on Phase 1 and 2 trials and submitting applications for the conduct of Phase 3 clinical trials of their candidate vaccine.

COVID-19 VACCINE
Philstar
  • Latest
  • Trending
Latest
Are you sure you want to log out?
X
Login

Philstar.com is one of the most vibrant, opinionated, discerning communities of readers on cyberspace. With your meaningful insights, help shape the stories that can shape the country. Sign up now!

FORGOT PASSWORD?
SIGN IN
or sign in with